Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 3Liver Neoplasms 2Head and Neck Neoplasms 2Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Lung Neoplasms 1Liver Cirrhosis 1Hypoxia 1Gliosarcoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 72Brachytherapy 31Radiotherapy 26Paclitaxel 23Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 21human papillomavirus vaccine, L1 type 16, 18 20Topotecan 18Papillomavirus Vaccines 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 16pembrolizumab 14Radiation 12Gemcitabine 12Early Intervention, Educational 12Colposcopy 12Methods 11Magnetic Resonance Spectroscopy 11atezolizumab 10Radiotherapy, Intensity-Modulated 10Blood Specimen Collection 10Papanicolaou Test 9Docetaxel 9Vaccines, Synthetic 8Platinum 8Nivolumab 8Ipilimumab 8Counseling 81,2-diaminocyclohexaneplatinum II citrate 8Vaccines 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Uterine Cervical Neoplasms × fluoromisonidazole × Clear all
NCT00559377 2016-12-30

FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 7 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡